All of our offerings
Beyond Air
September, 2025
Warrant Inducement
Exclusive Placement Agent
$3,250,000
Femasys
August, 2025
Joint Bookrunner
$8,000,000
Calidi Biotherapeutics, Inc.
August, 2025
Follow-On Offering
Co-Manager
$6,000,000
Nasus Pharma
August, 2025
Initial Public Offering
Lead Left Bookrunner
$10,000,000
Nuvectis Pharma
July, 2025
Advisory Services
Financial Advisor
Curis, Inc.
July, 2025
Registered Direct Offering and Concurrent Private placement
Placement Agent
$7,000,000
Algorithm Sciences
June, 2025
Series D Private Placement
Exclusive Placement Agent
$6,500,000
Nucana
June, 2025
At-The-Market-Offering
Sales Agent
$100,000,000
Algorithm Sciences
June, 2025
Convertible Debenture
Exclusive Placement Agent
$3,500,000
Nucana
May, 2025
Registered Direct Offering
Sole Placement Agent
$7,000,000
Adaptin Bio
April, 2025
Alternative Public Offering (APO) Private Placement
Exclusive Placement Agent
$7,700,000
Quantum Space
March, 2025
Direct Investment
Series A
$50,000,000
Curis, Inc.
March, 2025
Registered Direct and Concurrent Private Placement
Sole Placement Agent
$10,000,000
BiomX
February, 2025
Registered Direct and Concurrent Private Placement
Sole Placement Agent
$12,000,000
Palatin Technologies Inc.
February, 2025
Registered Direct and Concurrent Private Placement
Co-Placement Agent
$4,700,000
X-Energy
January, 2025
Direct Investment
Series C-1 Preferred
$700,000,000
Hepion Pharmaceuticals
January, 2025
Follow-On Offering
Sole Placement Agent
$9,000,000
Ovation.io
January, 2025
Convertible Note Offering
Exclusive Placement Agent
$6,000,000
Amesite Inc.
January, 2025
Follow-On Offering
Joint Bookrunner
$3,600,000
Voltron Therapeutics
December, 2024
Convertible Note Offering
Exclusive Placement Agent
$4,780,000
Curis, Inc.
October, 2024
Registered Direct and Concurrent Private Placement
Placement Agent
$12,100,000
IN8bio, Inc.
October, 2024
Advisory Services
Financial Advisor
Beyond Air
September, 2024
Private Placement
Co-Placement Agent
$20,600,000
Algorithm Sciences
August, 2024
Seed Financing Convertible Bridge Notes
Exclusive Placement Agent
$1,500,000
PD Theranostics – Ovation
August, 2024
Private Placement and Concurrent Merger
Exclusive Placement Agent
$9,500,000
Hepion Pharmaceuticals
July, 2024
Unsecured Non-Convertible Note
Financial Advisor
$2,900,000
Algorithm Sciences
June, 2024
Spin Out – Infusyn Therapeutics
Sole Advisor
$5,000,000
Applied DNA Sciences
May, 2024
Follow-On Offering
Co-Placement Agent
$12,000,000
AerWave Medical
May, 2024
Convertible Debentures
Introducing Broker
$5,000,000
Soleno Therapeutics
May, 2024
Follow-On Offering
Lead Manager
$158,700,000
Beyond Air
March, 2024
Registered Direct Offering
Co-Placement Agent
$16,000,000
BiomX, Inc.
March, 2024
Private Placement
Placement Agent
$50,000,000
Viking Therapeutics
March, 2024
Follow-On Offering
Co-Manager
$632,500,000
Oragenics, Inc.
March, 2024
Follow-On Offering
Joint Bookrunning Manager
$2,100,000
Evoke Pharma
February, 2024
Follow-On Offering
Joint Bookrunner
$7,500,000 of up to $30,000,000
Perfect Moment
February, 2024
Initial Public Offering
Joint Bookrunner
$8,000,000
Infusyn Therapeutics
January, 2024
Series D Preferred
Introducing Broker
$4,000,000
Beyond Air
January, 2024
Advisory Services
EyePoint Pharmaceuticals
December, 2023
Follow-On Offering Common Stock
Co-Manager
$230,000,000
MAIA Biotechnology
November, 2023
Common Stock & Concurrent Private Placement
Financial Advisor
Soleno Therapeutics
October, 2023
Common Stock & Concurrent Private Placement
Lead Manager
$129,000,000
Cingulate
September, 2023
Advisory Services
MAIA Biotechnology
August, 2023
Advisory Services
BioSigTechnologies
May, 2023
Pipe Transaction
At the Market Offering
$2,500,000
PD Theranostics
April, 2023
Series A Financing
Exclusive Placement Agent
$3,000,000
Service Robotics Inc.
April, 2023
Secured Convertible Debenture
Introducing Broker
$3,000,000
Viking Therapeutics
March, 2023
Follow-On Offering
Co-Manager
$287,500,000
Guerilla RF, Inc
February, 2023
PIPE Transaction
Exclusive Placement Agent
$9,200,000
Hoth Therapeutics
February, 2023
PIPE Transaction
Financial Advisor
$10,000,000
BioSig Technologies
January, 2023
PIPE Transaction
Introducing Broker
$7,300,000
NLS Pharmaceutics
December, 2022
Private Placement
Investor: BVF Partners L.P. Exclusive Introducing Broker
$10,000,000 of up to $30,000,000
NLS Pharmaceutics
October, 2022
Private Placement
Sole Placement Agent
$4,000,000
Perfect Moment
October, 2022
Private Placement
Exclusive Placement Agent
$6,000,000
Silo Pharma
September, 2022
Follow-On Offering
Sole Bookrunner
$5,750,000
Amesite, Inc
August, 2022
Registered Direct Offering
Sole Placement Agent
$2,300,000
BioSig Technologies
June, 2022
Follow-On Offering Common Stock
Sole Bookrunner
$3,500,000
Perfect Moment
June, 2022
Secured Convertible Note
Exclusive Placement Agent
$10,000,000
Odyssey Group International Inc.
May, 2022
PIPE Common Stock and Warrants
Exclusive Placement Agent
$1,420,430
Soleno Therapeutics
March, 2022
Follow-On Offering Common Stock and Warrants
Co-Manager
$15,000,000
Amesite, Inc.
February, 2022
Follow-On Offering Common Stock
Sole Bookrunner
$3,000,000
Cohen & Steers
February, 2022
Initial Public Offering Common Stock
Initial Public Offering
$367,886,900
Pimco Access Income Fund
January, 2022
Initial Public Offering Common Stock
Co-Manager
$866,000,000
MEI Pharma
December, 2021
PIPE Transaction Follow-On Offering Common Stock
Co-Manager
$52,325,000
Cingulate Inc.
December, 2021
Initial Public Offering Common Stock and Warrants
Co-Lead Bookrunner
$25,000,000
Voltron Therapeutics
November, 2021
Series B Preferred Offering
Exclusive Placement Agent
$4,000,000
EyePoint Pharmaceuticals
November, 2021
Follow-On Offering Common Stock
Financial Advisor
$115,000,000
Guggenheim Active Allocation Fund
November, 2021
Initial Public Offering Common Stock
Co-Manager
$655,000,000
aTyr Pharma Inc.
September, 2021
Follow-On Offering Common Stock
Lead Manager
$86,250,000
BlackRock ESG Capital Alloc. Trust
September, 2021
Initial Public Offering Common Stock
Co-Manager
$2,040,000,000
BioSig Technologies
July, 2021
Follow-On Offering Common Stock
Sole Bookrunner
$10,000,000
Perfect Moment
May, 2021
Private Placement
Exclusive Placement Agent
$6,000,000
Aldeyra Therapeutics
April, 2021
Follow-On Offering Common Stock
Co-Manager
$125,000,000
Algorithm Sciences
April, 2021
Series B Offering
Co-Manager
$5,000,000
iCAD Inc.
March, 2021
Follow-On Offering Common Stock
Co-Manager
$25,000,000
Blue Stem Properties, LLC
March, 2021
Exclusive Placement Agent
$11,000,000
Aerwave Medical
February, 2021
Series A Offering
Exclusive Placement Agent
$4,000,000
EyePoint Pharma
February, 2021
Follow-On Offering Common Stock
Financial Advisor
$115,000,000
Evoke Pharma
January, 2021
Follow-On Offering Common Stock
Sole Bookrunner
$14,375,000
Affimed
January, 2021
Follow-On Offering Common Stock
Co-Manager
$14,375,000
Curis Inc.
December, 2020
Follow-On Offering Common Stock
Lead Manager
$169,625,000
Delcath Systems
December, 2020
Follow-On Offering Common Stock
Financial Advisor
$22,247,000
Amesite, Inc
September, 2020
Initial Public Offering Common Stock
Sole Bookrunner
$15,000,000
PD Theranostics
August, 2020
Series A Offering
Exclusive Placement Agent
$3,000,000
Arcturus Therapeutics
July, 2020
Follow-On Offering Common Stock
Financial Advisor
$173,000,000
Voltron Therapeutics
June, 2020
Series A Preferred Offering
Exclusive Placement Agent
$3,500,000
Soleno Therapeutics
June, 2020
Follow-On Offering Common Stock
Co-Manager
$50,000,000
Amesite Inc
May, 2020
Exclusive Placement Agent
$1,000,000
ViralClear Pharmaceuticals
May, 2020
Private Placement Common Stock
Introducing Broker
$10,000,000
Delcath Systems
May, 2020
Follow-On Offering Common Stock
Co-Lead Manager
$22,000,000
Arcturus Therapeutics
April, 2020
Follow-On Offering Common Stock
Financial Advisor
$70,000,000
Hoth Therapeutics
March, 2020
Follow-On Offering Common Stock
Sole Bookrunner
$5,000,000
Ziopharm Oncology
February, 2020
Follow-On Offering Common Stock
Co-Manager
$90,000,000
Algorithm Sciences
February, 2020
Series A Offering
Exclusive Placement Agent
$3,500,000
Biosig Technologies
February, 2020
Follow-On Offering Common Stock
Sole Book-Runner
$10,000,000
EyePoint Pharmaceuticals
February, 2020
Follow-On Offering Common Stock
Co-Manager
$21,800,000
Beyond Air
December, 2019
Follow-On Offering Common Stock
Financial Advisor
$10,500,000
Affimed
November, 2019
Follow-On Offering Common Stock
Co-Manager
$34,500,000
Molecular Templates
November, 2019
Follow-On Offering Common Stock
Financial Advisor
$50,000,000
Soleno Therapeutics
October, 2019
Follow-On Offering Common Stock
Co-Manager
$15,400,000
Noxopharm, Ltd
July, 2019
Funding Facility
Sole Financial Advisor
$26,000,000
Icad, Inc
June, 2019
Follow-On Offering Common Stock
Financial Advisor
$9,000,000
Athenex, Inc
April, 2019
Block Trade
Sole Broker
$20,000,000
EyePoint Pharmaceuticals
March, 2019
Follow-On Offering Common Stock
Co-Manager
$20,000,000
Hoth Therapeutics
February, 2019
Initial Public Offering Common Stock
Sole Bookrunner
$7,000,000
Taiwan Liposome Company
November, 2018
Initial Public Offering Common Stock
Co-Manager
$21,750,000
Tiziana Life Sciences
November, 2018
Initial Public Offering Common Stock
Sole Bookrunner
$7,000,000
Molecular Templates, Inc
September, 2018
Follow-On Offering Common Stock
Lead Manager
$45,100,000
Viking Therapeutics
September, 2018
Follow-On Offering Common Stock
Follow-On Offering Common Stock
$175,800,000
Aldeyra Therapeutics
September, 2018
Follow-On Offering Common Stock
Co-Manager
$72,187,500
BioSig Technologies
August, 2018
PIPE Transaction Common Stock
Introducing Broker
$6,000,000
Aridis Pharmaceuticals
August, 2018
Initial Public Offering Common Stock
Co-Manager
$26,000,000
WatchTower Investments, LLC
August, 2018
Member Interests
$16,348,970
Athenex, Inc
July, 2018
PIPE Transaction Common Stock
Exclusive Placement Agent
$100,000,000
Viking Therapeutics
June, 2018
Follow-On Offering Common Stock
Financial Advisor
$78,000,000
Sesen Bio
May, 2018
Follow-On Offering Common Stock
Financial Advisor
$48,000,000
MEI Pharma
May, 2018
PIPE Transaction Common Stock and Warrants
Co-Placement Agent
$75,000,000
Sesen Bio
March, 2018
Registered Direct Common Stock and Warrants
Exclusive Placement Agent
$10,000,000
Gemphire
February, 2018
Follow-On Offering Common Stock
Co-Manager
$22,000,000
Affimed
February, 2018
Follow-On Offering Common Stock
Financial Advisor
$23,000,000
Hoth Therapeutics
February, 2018
Private Placement Series A Preferred Warrants
Exclusive Placement Agent
$3,102,480
AIT Therapeutics
February, 2018
PIPE Transaction Warrants
Exclusive Placement Agent
$9,820,154.54
Athenex, Inc
January, 2018
Follow-On Offering Common Stock
Co-Manager
$65,575,000
Social T Partners
February, 2011 - December, 2017
Member Interests
$16,137,216
Fennec Pharmaceuticals
December, 2017
Follow-On Offering Common Stock
Financial Advisor
$20,000,000
Cytori Therapeutics
November, 2017
Rights Offering Convertible Preferred Common Stock
Financial Advisor
$10,000,000
Onconova Therapeutics
November, 2017
Registered Direct Common Stock
Sole Placement Agent
$1,380,000
ADMA Biologics
November, 2017
Follow-On Offering Common Stock
Financial Advisor
$36,500,000
Flexion Therapeutics
October, 2017
Follow-On Offering Common Stock
Financial Advisor
$122,400,000
Asterias Biotherapeutics
October, 2017
Registered Direct Common Stock
Financial Advisor
$10,400,000
US Gold Corporation
October, 2017
Confidentially Marketed Public Offering Common Stock
Sole Bookrunner
$2,500,000
Hoth Therapeutics
September, 2017
Private Placement Common Stock
Exclusive Placement Agent
$2,037,000
SearchLight Investments, LLC
September, 2017
Member Interests
$17,382,227
MabVax Therapeutics, Inc.
September, 2017
Registered Direct Common Stock
Sole Placement Agent
$2,000,000
Aldeyra Therapeutics
September, 2017
Follow-On Offering Common Stock
Lead Manager
$28,800,000
Cooltech Holding Corp.
June, 2017
Private Placement Common Stock
Exclusive Placement Agent
$5,688,055
Spherix, Inc.
June, 2017
Follow-On Offering
Sole Bookrunner
$2,500,000
Flexion Therapeutics
May, 2017
Convertible Note
Financial Advisor
$175,000,000
MabVax Therapeutics, Inc.
May, 2017
Convertible Note Common and Preferred Stock
Sole Bookrunner
$4,100,000
Repros Therapeutics
May, 2017
Confidentially Marketed Public Offering Common Stock and Warrants
Sole Bookrunner
$3,000,000
Onconova Therapeutics
April, 2017
Confidentially Marketed Public Offering Common Stock
Sole Bookrunner
$5,963,517
Gemphire
March, 2017
PIPE Transaction Common Stock & Warrants
Co-Manager
$12,500,000
Therapix Biosciences
March, 2017
Initial Public Offering Common Stock
Sole Bookrunner
$13,800,000
AIT Therapeutics
March, 2017
PIPE Transaction Common Stock and Warrants
Placement Agent
$10,200,000
BioSig Technologies
March, 2017
PIPE Transaction Common Stock and Warrants
Exclusive Placement Agent
$4,349,954
Function(x), Inc.
February, 2017
Follow-On Offering Common Stock
Joint Bookrunner
$5,000,000
Aldeyra Therapeutics
February, 2017
Follow-On Offering Common Stock
Lead Manager
$10,000,000
Medovex Corporation
February, 2017
PIPE Transaction Common Stock & Warrants
Exclusive Placement Agent
$3,022,000
Affimed
January, 2017
Follow-On Offering Common Stock
Financial Advisor
$19,170,000
Pershing Gold Corporation
December, 2016
Confidentially Marketed Public Offering Common Stock
Lead Underwriter
$7,500,000
Towerstream Corporation
November, 2016
Confidentially Marketed Public Offering Common Stock
Sole Bookrunner
$4,000,000
US Gold Corporation
October, 2016
Private Placement Common Stock
Exclusive Placement Agent
$12,000,000
FTE Networks, Inc.
October, 2016
PIPE Transaction Common Stock & Warrants
Exclusive Placement Agent
$2,990,000
Protea Biosciences Group, Inc.
September, 2016
Convertible Debenture
Exclusive Placement Agent
$2,990,000
Spherix, Inc.
August, 2016
Confidentially Marketed Public Offering Common Stock
Sole Bookrunner
$2,500,000
MabVax Therapeutics, Inc
August, 2016
Follow-On Offering Common Stock & Warrants
Sole Bookrunner
$9,438,750
Alimera Sciences
August, 2016
Follow-On Offering Common Stock
Co-Manager
$25,000,000
ImmunoCellular
August, 2016
Follow-On Offering Common Stock
Lead Manager
$7,400,000
Gemphire
August, 2016
Initial Public Offering Common Stock
Co-Manager
$30,000,000
Flexion
June, 2016
Follow-On Offering Common Stock
Co-Manager
$77,000,000
PhaseRx
May, 2016
Initial Public Offering Common Stock
Joint Bookrunner
$18,500,000
ADMA Biologics
April, 2016
Follow-On Offering Common Stock
Financial Advisor
$14,200,000
Medovex Corporation
April, 2016
PIPE Transaction Common Stock & Warrants
Placement Agent
$1,398,033
Regenmed Therapeutics
March, 2016
Sale of Company
Financial Advisory
Pershing Gold Corporation
March, 2016
PIPE Transaction Common Stock
Exclusive Placement Agent
$6,890,000
ContraVir Pharmaceuticals
March, 2016
Follow-On Offering Common Stock
Sole Bookrunner
$7,000,000
Red Zone Investments, LLC
March, 2016
Member Interests
$11,926,825
Aeolus Pharmaceuticals
December, 2015
PIPE Transaction Common Stock
Exclusive Placement Agent
$6,750,000
Cerecor, Inc.
October, 2015
Initial Public Offering Common Stock & Warrants
Lead Manager
$26,000,000
MabVax Therapeutics, Inc.
October, 2015
Follow-On Offering Common Stock & Warrants
Sole Bookrunner
$2,750,000
ContraVir Pharmaceuticals
October, 2015
Follow-On Offering Common Stock & Warrants
Sole Bookrunner
$15,000,000
Sevion Therapeutics
July, 2015
PIPE Transaction Common Stocks & Warrants
Exclusive Placement Agent
$7,325,217
AirBase Technology Partners, LLC
July, 2015
Member Interests
$19,124,663
Pre-Flight Partners, LLC
October, 2011 - July, 2015
Member Interests
$10,841,677
Bluebird Investment Partners
April, 2012 - June, 2015
Member Interests
$13,848,670
Face-Off Partners II, LLC
September, 2010 - June, 2015
Member Interests
$22,012,097
Actinium Pharmaceuticals
June, 2015
Registered Direct
Exclusive Placement Agent
$5,000,000
AirLift Investments, LLC
May, 2015
Member Interests
$40,877,660
Viking Therapeutics
May, 2015
Member Interests Initial Public Offering
Sole Bookrunner
$40,877,660
Aldeyra Therapeutics
May, 2015
Follow-On Offering Common Stock
Co-Manager
$20,250,000
BioSig Technologies
April, 2015
Follow-On Offering Common Stock
Exclusive Placement Agent